Euroopa Liit - eesti - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ire healthcare limited - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Eesti - eesti - Ravimiamet

medochemie limited - ranitidiin - süste-/infusioonilahus - 25mg 1ml 2ml 100tk; 25mg 1ml 2ml 5tk

Eesti - eesti - Ravimiamet

pro.med.cs praha a.s. - ranitidiin - õhukese polümeerikattega tablett - 150mg 20tk; 150mg 60tk

Eesti - eesti - Ravimiamet

pro.med.cs praha a.s. - ranitidiin - õhukese polümeerikattega tablett - 75mg 20tk; 75mg 10tk

Eesti - eesti - Ravimiamet

accord healthcare limited - ranitidiin - õhukese polümeerikattega tablett - 75mg 6tk; 75mg 10tk; 75mg 60tk; 75mg 12tk; 75mg 24tk; 75mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - riociguat - hüpertensioon, kopsuvähk - antihüpertensiivsed ravimid kopsuarteri hüpertensioonile - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektiivsust on näidatud pah elanikkonnale, sh aetiologies idiopaatiline või pärilik pah või pah seotud sidekoe haigus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - omeprasool - gastroresistentne kõvakapsel - 10mg 56tk; 10mg 30tk; 10mg 100tk; 10mg 60tk; 10mg 280tk; 10mg 28tk; 10mg 15tk; 10mg 14tk; 10mg 50tk

Eesti - eesti - Ravimiamet

olainfarm as - omeprasool - gastroresistentne kõvakapsel - 20mg 60tk; 20mg 30tk; 20mg 56tk; 20mg 28tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - omeprasool - gastroresistentne kõvakapsel - 20mg 56tk; 20mg 500tk; 20mg 98tk; 20mg 15tk; 20mg 14tk; 20mg 140tk; 20mg 7tk; 20mg 280tk; 20mg 60tk; 20mg 90tk; 20mg 30tk; 20mg 50tk; 20mg 28tk